Robert C. Doebele, MD, PhD

07/22/2023

Newly published work by my former graduate student, Laura Schubert as well as Anh Le and the Heasley and Nemenoff Labs. We developed a rapid way to screen and induce CRISPR-based oncogenic gene fusions. We demonstrated successful induction of Kif5b-Ret, Trim24-Ret, and Tpm3-Ntrk1 gene fusions in vitro as well as successful induction of lung tumors bearing Trim24-Ret in vivo. We believe this technique will help generate multiple novel syngeneic tumor models for oncogenic gene fusions which will aid in studying the role of immune therapies and the tumor microenvironment in these cancers. https://pubmed.ncbi.nlm.nih.gov/37470475/

04/07/2023

My lab is winding down at University of Colorado, but my current and former lab members still keeping up the productivity to the very end and getting out some interesting work. Thanks to the whole team including my former grad student, Laura Schubert, MD, PhD, former lab manager Anh Le and long time collaborator Lynn Heasley, PhD for pushing this project across the finish line. Very cool method to rapidly screen and induce CRISPR-mediated gene fusions and lung tumors.
https://www.biorxiv.org/content/10.1101/2023.04.06.535912v1

03/21/2022

Haven't posted here in a while, but a nice history of my career path and of TRK inhibitor development with a shout out to many of my colleagues and mentors.

In this episode of Lung Cancer Considered, host Dr. Narjust Duma talks with Dr. Robert C. Doebele, Co-Founder and Chief Scientific Officer, Rain Therapeutics ab ...

09/11/2020

Proud of Dr. Dimou and his work published on matching of mutant specific neoantigens from patients with EGFR mutation positive NSCLC and survival outcomes demonstrating a potential role for CD8-mediated immune responses in select patients. Thanks to AACR-Conquer Cancer Foundation of ASCO Young Investigator Translational Cancer Research Award that funded his work!

Cancer-associated mutations have the potential to generate neoantigens and elicit CD8 positive T cell dependent adaptive immune responses. There are currently no reports of CD8 positive T cells with specificity for neoepitopes generated by EGFR mutations, which are driver oncogenes in a subset of pa...

03/09/2020

Very proud of my former graduate student (and first graduate student) in earning the NCI Pathway to Independence Award (K99/R00)!

Aria Vaishnavi, PhD, a post-doctoral fellow at Huntsman Cancer Institute at the University of Utah has received the first annual National Cancer Institute Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers. The “Early K99” grant supports researchers who need only ...

01/09/2020

Good news that lung cancer advancements leading the way in cancer death reductions, but never enough! University of Colorado Cancer Center

Breakthrough treatments for lung cancer and melanoma have driven down cancer mortality overall — and from 2016 to 2017 spurred the largest-ever decline.

12/12/2019

A heartfelt thanks to everyone involved in the entrectinib studies - patients, investigators, sponsors, coordinators. Entrectinib in ROS1 NSCLC and NTRK solid tumors now online at Lancet Oncology. University of Colorado Anschutz Medical Campus University of Colorado Cancer Center

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30691-6/fulltext

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30690-4/fulltext

Entrectinib induced durable and clinically meaningful responses in patients with NTRK fusion-positive solid tumours, and was well tolerated with a manageable safety profile. These results show that entrectinib is a safe and active treatment option for patients with NTRK fusion-positive solid tumours...

11/14/2019

So wonderful to see so many lung cancer survivors at our annual event. Truly inspiring!

This is "CU Anschutz Cancer Center Lung Cancer Survivors Celebration 2019" by Catch It In Time on Vimeo, the home for high quality videos and the people…

10/23/2019

So grateful to and other patients who donate tumor samples for research. University of Colorado Cancer Center

The ROS1ders advocacy group is 500 patients strong and they are helping researchers establish cell lines to improve understanding of rare ROS1-positve cancers.

10/14/2019

With the recent approvals of larotrectinib and entrectinib, we now know that we can target multiple different tumor types as long as they have the same biology - but, what about drug resistance? A look through the literature suggests that cancer cells turn to the same mechanisms over and over again for drug resistance, regardless of oncogene, drug, and tumor type. University of Colorado Cancer Center

Recent approvals of TRK inhibitors have demonstrated the success of a tumor agnostic approach to oncogene-targeted therapy across cancers. Collective …

10/10/2019

Congrats Tejas!

CU Cancer Center member Tejas Patil, MD, first physician worldwide to earn the prestigious John Fisher Legacy Award | Lung Cancer Research

09/18/2019

So excited that entrectinib is now available to all after FDA approval!

AURORA, Colo. -- Cheryl Rathke is quite the success story at the University of Colorado Cancer Center. The UCHealth patient participated in a clinical trial for a treatment that the Food and Drug Administration recently approved. It’s a new targeted medicine for rare and difficult to treat cancers...